Evidence map›Paper›PMID 35200573›Full record

GuidelineCurrent oncology (Toronto, Ont.)2022

A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre.

Parneet K Cheema, Marco A J Iafolla, Massey Nematollahi, FeRevelyn Berco, Deepanjali Kaushik, Priscilla Matthews, William R Raskin, Kirstin A Perdrizet, Shaan Dudani, Juhi Husain and 4 more

Open access · goldAbstract readGuideline
In one paragraph

Guideline in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Parneet K CheemaMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Marco A J IafollaMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Massey NematollahiMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
FeRevelyn BercoMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Deepanjali KaushikMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Priscilla MatthewsMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
William R RaskinMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Kirstin A PerdrizetMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.ORCID 0000-0002-8746-665X
Shaan DudaniMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.ORCID 0000-0003-4958-381X
Juhi HusainMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Margaret BalcewiczMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Philip G KuruvillaMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Stephen M ReingoldMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Henry J ConterMedical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
William Osler Health System · CAUniversity of Toronto · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detailing the implementation of cancer immunotherapy in routine practice was developed. The approach focuses on four key steps: (1) identification of patient educators; (2) development of patient education materials; (3) development of patient monitoring tools; (4) involvement and education of multidisciplinary teams. Here, we provide an in-depth description of what was included in each step and how we integrated the different elements of the program. For each step, resources, tools, and materials that may be useful for patients, healthcare providers, and multidisciplinary teams were developed or modified based on existing materials. At our centre, the program led to improved patient comprehension of irAEs, the ability to act on symptoms (patient self-efficacy), and low rates of emergency room visits at first presentation for irAEs. We recognize that centres may need to tailor the approaches to their institutional policies and encourage centres to adapt and modify the forms and tools according to their needs and requirements.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsEmergency Service, HospitalHumansImmunotherapyOntarioPractice Guidelines as TopicImmune Checkpoint Inhibitorscancer immunotherapyimmune checkpoint inhibitorsimmune-related adverse eventsmultidisciplinary teamspatient education

Identifiers

PMID35200573
PMCPMC8870472
OpenAlexW4210565879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.